$1.73
+0.07 (+4.22%)
Open$1.60
Previous Close$1.66
Day High$1.76
Day Low$1.56
52W High$12.23
52W Low$1.65
Volume—
Avg Volume275.1K
Market Cap22.38M
P/E Ratio—
EPS$-10.40
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,427.2% upside
Current
$1.73
$1.73
Target
$43.72
$43.72
$35.70
$43.72 avg
$58.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.83M | 4.18M | 3.97M |
| Net Income | -258,165,367 | -1,151,363 | -1,086,006 |
| Profit Margin | -16,993.3% | -27.6% | -27.4% |
| EBITDA | -256,894,157 | -1,394,086 | -1,159,340 |
| Free Cash Flow | — | -921,744 | -1,324,564 |
| Rev Growth | — | +11.5% | +10.2% |
| Debt/Equity | 0.33 | 0.72 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |